Clinical observation of adefovir dipivoxil in the treatment of hepatitis B ptients with HBeAg positive

VernacularTitle:阿德福韦酯治疗HBeAg阳性的慢性乙型肝炎临床观察
Author: Jian WANG
Publication Type:Journal Article
Keywords: Adefovir dipivoxil; Chronic Hepatitis B; Hepatitis B virus e antigen; Randomized controlled trial
From: Chinese Journal of Primary Medicine and Pharmacy 2013;20(7):986-988
CountryChina
Language:Chinese
Abstract: Objective To evaluate the safety and effect of adefovir dipivoxil (ADV) on hepatitis B in HBeAgpositive patients.Methods 131 patients were divided into two groups randomly.Two groups were treated with ADV (10mg/d)and matrine (0.6g/d),respectively.The rate of HBV negative,the normalization rates of ALT,HBeAg loss and anfi-HBe seroconversion were evaluated respectively.Results After 12 weeks of treatment,the rate of HBV negative,the normalization rates of ALT,HBeAg loss and anti-HBe seroconversion of ADV were all significantly higher than those of matrine group(53.2％ vs 7.8％,36.0％ vs 8.7％,13.6％ vs 3.1％,6.2％ vs 0,respectively,x2 =56.32,23.18,all P ＜ 0.01).Conclusion The domestic ADV superior to matrine in HBeAg-positive patients.